Teleflex (TFX) has caught investor attention after starting patient enrollment in the global BIOMAG-III Study for its Freesolve Resorbable Magnesium Scaffold, alongside progress on earlier BIOMAG trials and the release of long-term clinical data.
See our latest analysis for Teleflex.
Teleflex’s recent BIOMAG milestones and $500 million senior notes issuance come as the stock trades at $129.86, with a 90 day share price return of 11.74% but a 5 year total shareholder return that has declined 67.17%. This suggests that momentum has picked up recently, while longer term holders have faced significant weakness.
If Teleflex’s cardiac scaffold work has your attention, this could be a good moment to broaden your watchlist and look at 39 healthcare AI stocks
With Teleflex trading at $129.86, an indicated 43.43% intrinsic discount and an 11.74% 90 day return, the key question is whether you are seeing mispricing today or a market that is already pricing in tomorrow’s growth potential.
Most Popular Narrative: 9.6% Undervalued
Teleflex’s most followed narrative pegs fair value at $143.67 versus the $129.86 last close, framing the BIOMAG program and portfolio reset as central to the story.
The recent acquisition of BIOTRONIK's Vascular Intervention business is expected to drive sustainable revenue growth of 6% or better annually beginning in 2026 and provide near-term EPS accretion by expanding Teleflex's presence in the high-growth interventional cardiology and endovascular procedures market, improved access to the cath lab and cross-selling opportunities are likely to boost topline revenue and margins.
Want to see what is baked into that fair value for Teleflex? The narrative leans on faster earnings growth, richer margins, and a premium future earnings multiple. Curious which assumptions really do the heavy lifting here and how sensitive they are to execution on the BIOTRONIK integration and procedure volumes? The full story joins those moving parts into one valuation argument.
Result: Fair Value of $143.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Teleflex narrative still leans on a very high future P/E multiple and assumes smoother BIOTRONIK integration; both of these points could be challenged if execution stumbles.
Find out about the key risks to this Teleflex narrative.
Next Steps
Reading this Teleflex story, do you see more to like or more to question? Act while the details are fresh and weigh both sides through the 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Teleflex?
If Teleflex has sharpened your focus on quality, do not stop here. Broaden your opportunity set now using targeted stock ideas built from the Simply Wall Street Screener.
- Target potential mispricing by reviewing companies that currently screen as promising on value and fundamentals through the 44 high quality undervalued stocks.
- Prioritise resilience by scanning companies that score well on financial strength and staying power with the 71 resilient stocks with low risk scores.
- Spot potential up and comers with strong underlying numbers before they hit the spotlight by checking the screener containing 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com